📅 PUBMED DAILY TRIAGE — 2026-06-13 (Saturday)

Window: 2026-06-12T09:00Z → 2026-06-13T09:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~75 candidates | Formally classified: 35 High priority: 3 | Standard: 31 | Low/archive: 1 | Unsolicited finds: 0 Run status: ✅ SUCCESS

Notable: Strong rebound from yesterday's zero-HIGH run (Friday). 3 HIGH-priority articles today including a Nat Cancer CPTAC AML flagship. 6 of 9 deferred articles from 2026-06-12 cleared (2 still deferred: 42274988, 42274032).

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies

TR-2026-06-13-001 / PMID 42286338 · Integrated proteogenomic and metabolomic profiling of AML to identify molecular subtypes and therapy targets · 9/10 · Nature Cancer CPTAC flagship study across 13 omics modalities in 173 treatment-naive AML patients — defines new subtype architecture and validates MTA1 as a panobinostat resistance driver via ML, with direct implications for precision AML therapy selection.

Early Cancer Detection / Liquid Biopsy (Deferred 2026-06-12)

TR-2026-06-13-002 / PMID 42274209 · A Neural Network-Enabled, Enzymatic cfDNA Methylation Assay for Colorectal Cancer Early Detection · 8/10 · Cancer Prev Res; Weill Cornell; non-NGS cfDNA methylation assay (40 CpGs + neural network) achieves 92.3% sensitivity and 100% early-stage sensitivity at 97.4% specificity in 216 plasma samples — potentially scalable CRC population screening tool.

Novel Therapeutics / Liquid Biopsy

TR-2026-06-13-003 / PMID 42285994 · Cadonilimab + chemotherapy in PD-L1-negative advanced NSCLC: phase II · 8/10 · Nature Commun; Phase II (n=50); PD-1/CTLA-4 bispecific antibody + platinum doublet achieves ORR 66%, DCR 100%, median OS NR in PD-L1-negative NSCLC (a major immunotherapy-excluded subgroup); cfDNA methylation biomarker predicts response 5 cycles before imaging.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• TR-2026-06-13-009 / PMID 42286378 · Emerging treatment strategies for newly diagnosed DLBCL · 6/10 · Treatment Innovation
• TR-2026-06-13-010 / PMID 42286308 · Long-term mortality modeling in pediatric HL survivors after reduced RT · 6/10 · Prevention (JNCI, CCSS-based simulation)
• TR-2026-06-13-011 / PMID 42286309 · MCM2 hub gene immune prognosis in MM, n=751, + PD1/PD-L1 synergy · 6/10 · Drug Development
• TR-2026-06-13-029 / PMID 42286371 · Sex differences in cancer incidence in HIV+, 3.9M person-years, JNCI · 5/10 · Public Health

CBC-Based Diagnostics & ML

• TR-2026-06-13-012 / PMID 42281693 · Neutrophil CD64/CD66b/thioredoxin for delayed FRI, n=637, AUC 0.93, NPV 99% · 6/10 · Diagnostics (prospective)
• TR-2026-06-13-028 / PMID 42284544 · ML RSF prognostic model for intermediate trophoblastic tumors, n=236, C=0.816 · 5/10 · Diagnostics

Early Cancer Detection / Liquid Biopsy

• TR-2026-06-13-006 / PMID 42286014 · Real-world ctDNA CDK4/6i resistance in HR+ metastatic breast cancer · 7/10 · Genomics/Precision Medicine
• TR-2026-06-13-007 / PMID 42286129 · HPV cfDNA for HPV-OPC recurrence monitoring, n=59, 3–8 months early signal · 7/10 · Early Detection (prospective)
• TR-2026-06-13-008 / PMID 42276999 · LLM benchmarking for cfRNA biomarker discovery, Nat Commun · 7/10 · AI/ML Diagnostics [deferred]
• TR-2026-06-13-013 / PMID 42277406 · EV-miRNA panel (miR-141/10b/550a/16) for PCa vs BPH liquid biopsy · 6/10 · Early Detection [deferred]
• TR-2026-06-13-025 / PMID 42286104 · Multimodal ML pipeline CRC recurrence, n=86, AUC 0.695, exploratory · 5/10 · Early Detection

AI/ML in Clinical Diagnostics

• TR-2026-06-13-014 / PMID 42286391 · Early 1h 99mTc-DPD scintigraphy equivalent for ATTR-CM (n=50, external validation) · 6/10 · Diagnostics
• TR-2026-06-13-026 / PMID 42286429 · ML + MR genetic diagnostic markers for SLE (GBP1, IFI6, OAS3) · 5/10 · Diagnostics
• TR-2026-06-13-027 / PMID 42286382 · CDSegNet U-Net variant for Crohn's disease CTE segmentation (+11% IoU) · 5/10 · Diagnostics

Precision Oncology & Genomics

• TR-2026-06-13-005 / PMID 42286408 · RET fusions predict PTC recurrence (HR 14x), n=2,056, improves 2025 ATA RSS, JNCI · 7/10 · Genomics/PM
• TR-2026-06-13-015 / PMID 42286383 · Gut microbiome HCC biomarkers, AUC 0.96 liver model, MR-supported · 6/10 · Early Detection
• TR-2026-06-13-016 / PMID 42286232 · FIT stool microbiome CRC screening cohort n=925, NCI, Br J Cancer · 6/10 · Early Detection
• TR-2026-06-13-017 / PMID 42286231 · CRC tumor deposits + immune evasion + dose-dependent survival, n=845 · 6/10 · Diagnostics
• TR-2026-06-13-021 / PMID 42286316 · ICI in thymic malignancies n=42, TP53/CDKN2A biomarkers, NPJ Precis Oncol · 5/10 · Treatment Innovation

Novel Therapeutics

• TR-2026-06-13-018 / PMID 42286212 · SATB1 ablation destabilizes Tregs + boosts CD4 CAR-T clearance, EMBO Rep · 6/10 · Drug Development
• TR-2026-06-13-022 / PMID 42286319 · CAR-T for multiple sclerosis: CD19 targeting, deep remission in refractory MS (review) · 5/10 · Treatment Innovation

Cardiovascular-Metabolic

• TR-2026-06-13-019 / PMID 42286355 · Adipose tissue as humoral-neuronal metabolic hub, Nat Rev Endocrinol · 6/10 · Prevention/Drug Development
• TR-2026-06-13-034 / PMID 42286403 · Global T2DM trends review: 852.5M by 2050, 42.8% undiagnosed · 4/10 · Public Health

Aging & Longevity

• TR-2026-06-13-020 / PMID 42284535 · Race/ethnicity, hypertension, brain aging HABS-HD n=1,347, causal mediation, Neurology · 6/10 · Public Health
• TR-2026-06-13-023 / PMID 42284470 · Passive IoT monitoring for mental health in older cancer survivors (JMIR Cancer, n=41) · 5/10 · Mental Health
• TR-2026-06-13-024 / PMID 42283969 · Glymphatic system impairment in neurological disorders: AQP4 targets (review) · 5/10 · Other

Rare Diseases

• TR-2026-06-13-004 / PMID 42285302 · Social determinants of health in HAE: Black patients 2.25x higher hospitalization (JAIP, claims) · 7/10 · Public Health 🟡
• TR-2026-06-13-032 / PMID 42276024 · Rare disease nomenclature/coding global policy review, INSERM/Orphanet · 4/10 · Public Health

💡 UNSOLICITED FINDS

None today — sentinel scan top-10 candidates all already captured by watchlist queries.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 8 | Diagnostics: 9 | Genomics/Precision Medicine: 5 | Treatment Innovation: 5 | Public Health: 6 | Drug Development: 3 | Prevention: 2 | Mental Health: 1 | Other: 1

By evidence maturity:

• Validated: 17 | Exploratory: 16 | Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

• T1 Hematologic malignancies: 10 reviewed / 5 kept / 9 (42286338) ✅ HIGH
• T2 CBC/ML diagnostics: 5 reviewed / 3 kept / 6 (42281693)
• T3 Liquid biopsy/ctDNA: 10 reviewed (incl. 6 deferred) / 7 kept / 8 (42274209) ✅ HIGH
• T4 AI/ML diagnostics: 8 reviewed / 3 kept / 6 (42286391)
• T5 Precision oncology/genomics: 6 reviewed / 5 kept / 7 (42286408)
• T6 Novel therapeutics: 6 reviewed (42285994 shared T3/T6) / 4 kept / 8 (42285994) ✅ HIGH
• T7 Cardiovascular-metabolic: 5 reviewed / 2 kept / 6 (42286355)
• T8 Aging/longevity: 6 reviewed / 3 kept / 6 (42284535)
• T9 Rare diseases: 3 reviewed (incl. 1 deferred) / 2 kept / 7 (42285302)
• Sentinel: 10 reviewed / 0 new unsolicited

By source type: peer_reviewed: 35 | preprint: 0

By pipeline priority flag:

• 🟠 NOVEL_TREATMENT: 2 | 🔴 EARLY_CANCER_DETECTION: 3 | 🟡 UNDERSERVED_POPULATION: 6 | 🟢 NEAR_TERM_IMPLEMENTABLE: 9 | ⚪ PROMISING_PRELIMINARY: 13 | ⬜ NONE: 2

Topics with zero 8+ articles this run: T2 CBC/ML, T4 AI/ML, T5 Precision oncology, T7 Cardiovascular-metabolic, T8 Aging, T9 Rare diseases

🔧 RUN NOTES

• Window expansion: Not triggered (35 relevant records well above the 5-article expansion threshold).
• Deferred articles cleared: PMID 42274209 (T3) and 42276024 (T9) cleared from 2026-06-12 deferred set; 42277247, 42276999, 42277406, 42277396, 42276503 also cleared.
• Still deferred: 42274988 and 42274032 — unclear if T3 or T9 (overlap in prior state notes); carry forward to 2026-06-14.
• T2 CBC/ML: Only 10 raw results today — lowest-volume topic. Best article was neutrophil CD64/CD66b prospective cohort (n=637, score 6/10). Consider broadening T2 query if trend continues.
• T8 Aging: 28 raw results with humans[MeSH] filter. Adequate yield. Best candidate Neurology HABS-HD brain aging study narrowly scored 6/10 (STANDARD).
• Saturday publication cadence: Despite being a weekend, strong output today — 3 HIGH articles including Nat Cancer CPTAC AML landmark paper published Friday/Saturday.
• Rolling 7-day topics with zero HIGH (from state tracking): T7 Cardiovascular-metabolic has had no HIGH articles for 2 consecutive days. T8 Aging has had no HIGH articles for 3+ consecutive days.